This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 19.05% and 4.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 7.69% and 4.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -4.24% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 125% and 5.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -13.33% and 4.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
by Zacks Equity Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio
by Zacks Equity Research
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.
The Joint (JYNT) 2022 Visits Grow to 12.2M, Adds New Clinics
by Zacks Equity Research
The Joint's (JYNT) clinic network grows 19% year over year in 2022.
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.
UnitedHealth (UNH) Beats on Q4 Earnings, Retains 2023 View
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results gain from sustained membership growth in its UnitedHealthcare business.
Brookdale Senior Living (BKD) Q4 Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 14 straight months of year-over-year increases in weighted average occupancy level.
Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%
by Zacks Equity Research
Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 14.89% and 28.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Sotera Health Company (SHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -33.33% and 37.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LHC Group (LHCG) Q1 Earnings Surpass Estimates
by Zacks Equity Research
LHC (LHCG) delivered earnings and revenue surprises of 3.81% and 0.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Biodesix, Inc. (BDSX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.